ST. JOSEPH, Mich., July 8 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Keck Microarray Center at Yale has become a certified GeneGo Center of Excellence (COE). Yale researchers will have access to GeneGo’s MetaCore, training and advanced support.
The W. M. Keck Foundation Biotechnology Resource Laboratory (Keck Lab), one of the largest biotechnology laboratories of its kind in academia, is a world leader in the field of genomics and proteomics. The Keck Microarray Resource is also a part of the NIH Neuroscience-supported Yale Microarray Center for Research on the Nervous System. The Yale Microarray Center is one of four national centers which together form a Consortium that provide gene expression and genotyping services at significantly reduced costs to approximately 10,000 NIH-funded neuroscientists from 15 branches of NIH that are part of the NIH-Neuroscience Blueprint.
It is anticipated that MetaCore will be used at Yale to study basic and translational research; cancer biology; neuroscience research; and other clinical conditions. Overall, the COE will provide a pathway analysis environment and support for all the University’s researchers and will also act as a training facility for GeneGo.
“MetaCore is being heavily used by our users and we find it to be a very intuitive, easy to use and powerful tool for performing pathway analysis of the microarray data,” said Dr. Shrikant Mane, Director of Keck Microarray Resource.
“Neurosciences is one of the key diseases we have chosen to focus on this year, and working with Yale is important to GeneGo as they are a leader in this field,” said Julie Bryant, GeneGo’s VP of Business development. “We are very pleased to have them as a GeneGo Center of Excellence.”
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company’s web site at http://www.genego.com
MetaCore(TM), MetaBase(TM) MetaDrug(TM) , MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,
Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
